乳腺癌辅助双膦酸盐及其他骨改良药物应用:Cancer Care Ontario与美国临床肿瘤学会临床实践指南
该指南由Cancer Care Ontario与ASCO召集工作组和专家组,基于系统综述制定。推荐可考虑对适合辅助全身治疗的自然绝经或卵巢抑制/消融所致绝经后乳腺癌患者使用唑来膦酸或氯膦酸辅助治疗;地舒单抗数据尚不足以推荐。
要点
- 辅助双膦酸盐可减少绝经后非转移性乳腺癌患者骨复发并改善生存。
- 推荐可考虑唑来膦酸(4 mg静脉每6个月)或氯膦酸(1,600 mg/d口服)用于适合辅助全身治疗的绝经后患者。
- 治疗前应评估颌骨坏死和肾功能损害风险,并处理待解决的口腔健康问题。
核心结论
- 推荐可考虑唑来膦酸(4 mg静脉每6个月)或氯膦酸(1,600 mg/d口服)作为适合辅助全身治疗的绝经后乳腺癌患者的辅助治疗(若可用)。
- 地舒单抗可减少骨折,但长期生存数据仍需获得,目前数据不足以做出任何推荐。
- 需要进一步研究比较不同骨改良药物、剂量、给药间隔和疗程。
研究设计与样本
- Cancer Care Ontario与ASCO召集工作组和专家组,基于系统文献综述制定循证推荐。
主要发现
- 辅助双膦酸盐可减少绝经后非转移性乳腺癌患者的骨复发并改善生存。
- 本指南中绝经后包括自然绝经或由卵巢抑制或消融诱导的绝经。
- 复发风险较高的患者绝对获益更大,几乎所有试验的患者同时接受了全身治疗。
- 大多数研究评估了唑来膦酸或氯膦酸,其他双膦酸盐的数据极其有限。
- 地舒单抗可减少骨折,但长期生存数据仍需获得。
关键数值与推荐
- 推荐:若可用,可考虑唑来膦酸(4 mg静脉每6个月)或氯膦酸(1,600 mg/d口服)作为适合辅助全身治疗的绝经后乳腺癌患者的辅助治疗。
- 治疗前应评估颌骨坏死和肾功能损害的风险因素,并处理任何待解决的口腔或口腔健康问题。
- 地舒单抗辅助治疗数据看起来有前景,但目前不足以做出任何推荐。
- 使用这些药物减少低骨密度患者的脆性骨折超出本指南范围,本推荐不限制在这些情况下使用骨改良药物。
临床怎么用
- 对适合辅助全身治疗的绝经后乳腺癌患者,可考虑使用唑来膦酸(4 mg静脉每6个月)或氯膦酸(1,600 mg/d口服)辅助治疗(若可用)。
- 开始治疗前评估颌骨坏死和肾功能损害风险,并处理待解决的口腔健康问题。
- 目前不推荐辅助地舒单抗用于改善生存,因长期生存数据仍需获得。
局限性
- 其他双膦酸盐的数据极其有限。
- 地舒单抗的长期生存数据仍需获得。
- 需要进一步研究比较不同骨改良药物、剂量、给药间隔和疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. Results Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation. Absolute benefit is greater in patients who are at higher risk of recurrence, and almost all trials were conducted in patients who also received systemic therapy. Most studies evaluated zoledronic acid or clodronate, and data are extremely limited for other bisphosphonates. While denosumab was found to reduce fractures, long-term survival data are still required. Recommendations It is recommended that, if available, zoledronic acid (4 mg intravenously every 6 months) or clodronate (1,600 mg/d orally) be considered as adjuvant therapy for postmenopausal patients with breast cancer who are deemed candidates for adjuvant systemic therapy. Further research comparing different bone-modifying agents, doses, dosing intervals, and durations is required. Risk factors for osteonecrosis of the jaw and renal impairment should be assessed, and any pending dental or oral health problems should be dealt with prior to starting treatment. Data for adjuvant denosumab look promising but are currently insufficient to make any recommendation. Use of these agents to reduce fragility fractures in patients with low bone mineral density is beyond the scope of the guideline. Recommendations are not meant to restrict such use of bone-modifying agents in these situations. Additional information at www.asco.org/breast-cancer-adjuvant-bisphosphonates-guideline , www.asco.org/guidelineswiki , https://www.cancercareontario.ca/guidelines-advice/types-of-cancer/breast .
引用
- Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017. PMID: 28618241. doi:10.1200/JCO.2016.70.7257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。